The higher mutation frequencies were mainly related to BRAF V600E mutations in thyroid cancer (61.8%) and melanoma (43.6%) and IDH1 R132H mutations in low-grade glioma (70.1%; Fig 1B). This evidence concerns the gene IDH1 and thyroid gland carcinoma.